Literature DB >> 21463249

A single pill to treat postmenopausal hypertension? Not yet.

Licy L Yanes1, Damian G Romero, Radu Iliescu, Jane F Reckelhoff.   

Abstract

Postmenopausal women make up one of the fastest growing populations in the United States. Women typically have a higher incidence of cardiovascular disease following menopause. One of the major risk factors for cardiovascular disease is hypertension, and after menopause, blood pressure (BP) increases progressively in women. Also after menopause, the progression of renal disease increases in women compared with aged matched men. However, the mechanism(s) responsible for the post-menopausal increase in BP and renal injury are yet to be elucidated. Moreover the best therapeutic options to treat postmenopausal hypertension in women are not clear. Hypertension in postmenopausal women are usually associated with other cardiovascular risk factors, such as dyslipidemias, visceral obesity and endothelial dysfunction. Recently it became apparent that in a large number of hypertensive postmenopausal women, their BP is not well controlled with conventional antihypertensive medications. A clear understanding of the complex pathogenesis of postmenopausal hypertension is needed in order to offer the best therapeutic options for these women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463249      PMCID: PMC3462431          DOI: 10.2174/156802611796117667

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  56 in total

1.  In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET.

Authors:  Taofeek K Owonikoko; Maria E Fabucci; Philip R Brown; Nighat Nisar; John Hilton; William B Mathews; Hayden T Ravert; Paige Rauseo; Kathryn Sandberg; Robert F Dannals; Zsolt Szabo
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

2.  Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats.

Authors:  Lourdes A Fortepiani; Huimin Zhang; Lorraine Racusen; L Jackson Roberts; Jane F Reckelhoff
Journal:  Hypertension       Date:  2002-12-09       Impact factor: 10.190

3.  Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats.

Authors:  Ovidiu Baltatu; Cécile Cayla; Radu Iliescu; Dmitrii Andreev; Michael Bader
Journal:  Hypertension       Date:  2002-12-16       Impact factor: 10.190

4.  Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension.

Authors:  B T Alexander; K L Cockrell; A N Rinewalt; J N Herrington; J P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

5.  Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity.

Authors:  S Kousteni; T Bellido; L I Plotkin; C A O'Brien; D L Bodenner; L Han; K Han; G B DiGregorio; J A Katzenellenbogen; B S Katzenellenbogen; P K Roberson; R S Weinstein; R L Jilka; S C Manolagas
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

Review 6.  Dynamic modulation of baroreflex sensitivity in health and disease.

Authors:  G Parati; M Di Rienzo; G Mancia
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

7.  Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative.

Authors:  S Wassertheil-Smoller; G Anderson; B M Psaty; H R Black; J Manson; N Wong; J Francis; R Grimm; T Kotchen; R Langer; N Lasser
Journal:  Hypertension       Date:  2000-11       Impact factor: 10.190

8.  Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src.

Authors:  Mei Sun; Lin Yang; Richard I Feldman; Xia-meng Sun; Kapil N Bhalla; Richard Jove; Santo V Nicosia; Jin Q Cheng
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

9.  The human kidney is a progesterone-metabolizing and androgen-producing organ.

Authors:  M Quinkler; C Bumke-Vogt; B Meyer; V Bähr; W Oelkers; S Diederich
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats.

Authors:  Marie-Luise Gross; Marcin Adamczak; Thomas Rabe; Nevin Ali Harbi; Jan Krtil; Andreas Koch; Peter Hamar; Kerstin Amann; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

View more
  5 in total

1.  Chronic Estrogen Supplementation Prevents the Increase in Blood Pressure in Female Intrauterine Growth-Restricted Offspring at 12 Months of Age.

Authors:  Gwendolyn K Davis; Ashley D Newsome; Alyssa B Cole; Norma B Ojeda; Barbara T Alexander
Journal:  Hypertension       Date:  2019-05       Impact factor: 10.190

Review 2.  Yes! Sex matters: sex, the brain and blood pressure.

Authors:  Meredith Hay; Baojian Xue; Alan Kim Johnson
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

3.  Changes in Cardiovascular Health Status and the Risk of New-Onset Hypertension in Kailuan Cohort Study.

Authors:  Fei Gao; Xiaoxue Liu; Xizhu Wang; Shouhua Chen; Jihong Shi; Ying Zhang; Shouling Wu; Jun Cai
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

4.  The association between high-sensitivity C-reactive protein and hypertension in women of the CARDIA study.

Authors:  Imo A Ebong; Pamela Schreiner; Cora E Lewis; Duke Appiah; Azmina Ghelani; Mellissa Wellons
Journal:  Menopause       Date:  2016-06       Impact factor: 3.310

Review 5.  Hypertension and Age-Related Cognitive Impairment: Common Risk Factors and a Role for Precision Aging.

Authors:  Meredith Hay; Carol Barnes; Matt Huentelman; Roberta Brinton; Lee Ryan
Journal:  Curr Hypertens Rep       Date:  2020-09-03       Impact factor: 5.369

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.